Actively Recruiting
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
Led by baotai Liang · Updated on 2025-11-18
83
Participants Needed
1
Research Sites
108 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although neoadjuvant androgen deprivation therapy combined with radical prostatectomy reduced the positive rate of surgical margins, it did not show statistically significant improvement in prostate-specific antigen (PSA). At the same time, few trials reported pathological complete response (pCR) and minimal residual lesion (MRD). The purpose of this project is to verify the therapeutic effect of fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation in patients with locally advanced prostate cancer or oligometastatic prostate cancer before radical prostatectomy through randomized controlled clinical trials, so as to find an effective treatment for locally advanced prostate cancer or oligometastatic prostate cancer.
CONDITIONS
Official Title
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 85 years
- Histologically confirmed prostate cancer without small cell features
- Locally advanced prostate cancer (cT3-4) or oligometastatic prostate cancer with 5 or fewer bone or lymph node metastases
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Ability and willingness to provide informed consent and adhere to treatment and follow-up
You will not qualify if you...
- Previous or ongoing prostate cancer treatments including radiotherapy, chemotherapy, androgen deprivation therapy, or prostatectomy
- Presence of any serious medical, mental, or psychological condition that could affect treatment
- Allergy to study drugs
- Refusal to undergo radical prostatectomy
- Investigator's judgment deeming unsuitability for the clinical trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongda Hospital
Nanjing, Jiangsu, China
Actively Recruiting
Research Team
R
resident doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here